In addition, hepatic TG and FFA levels were markedly depleted after QGHXR treatment alone but increased by CXCL16 and QGHXR cotreatment, suggesting that CXCL16 treatment suppressed QGHXR-induced effects on hepatic steatosis (Figure 7). The gene discussed is CXCL16; the disease is fatty liver disease.